Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss
Postmenopausal women lost more weight with simultaneous medication use
2025-07-12
(Press-News.org) SAN FRANCISCO—Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” said Regina Castaneda, M.D., research fellow for the Division of Endocrinology at the Mayo Clinic in Jacksonville, Fla. “Previous studies of the medication semaglutide found similar results. Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications.”
Menopause-related hormonal changes often result in increased abdominal fat, decreased muscle mass and altered energy expenditure that leads to weight gain and puts millions of women at risk for developing heart disease and other serious health issues.
To confirm the hypothesis that concurrent menopause hormone therapy enhances the effectiveness of tirzepatide for weight loss in postmenopausal women, researchers conducted a real-world study using the electronic medical records of 120 postmenopausal women over a median duration of 18 months. The study included two cohorts: 40 women using menopause hormone therapy concurrently with tirzepatide and 80 women using tirzepatide alone.
The results showed superior total body weight loss percentage for women using tirzepatide plus menopause hormone therapy (17%) compared to those using tirzepatide alone (14%). In addition, a higher percentage of menopause hormone therapy users (45%) also achieved at least 20% total body weight loss, compared to 18% of menopause hormone therapy non-users.
“The information garnered through this new study provides important insights to develop more effective and personalized weight management interventions to reduce a postmenopausal woman’s risk of overweight and obesity-related health complications,” said Maria Daniela Hurtado Andrade, M.D., Ph.D., assistant professor of medicine and consultant for the Division of Endocrinology at the Mayo Clinic. “This study underscores the urgent need for further research to better understand how obesity medications and menopause hormone therapy work together. Gaining this knowledge could greatly improve the health and well-being of millions of postmenopausal women. It also points to the need for better strategies to make these treatments more accessible and available to those who need them.”
This research was funded by the National Institutes of Health Bridging Interdisciplinary Careers in Women’s Health Research Grant and the Mayo Clinic Center for Women's Health Research.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-07-12
SAN FRANCISCO—Metabolic health factors, including small increases in blood sugar, are the main drivers of change in the reproductive systems and sexual functioning of aging men, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“Although age and testosterone levels have long been considered an impetus for men’s declining sexual health, our research indicates that these changes more closely correlate with modest increases in blood sugar and other metabolic changes,” said Michael Zitzmann, ...
2025-07-12
SAN FRANCISCO—Strong emotional links between children with chronic conditions and their family caregivers suggest that improving parent well-being may directly benefit a child’s overall health and coping mechanisms, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
The study observed children with growth hormone deficiency and their caregivers to better understand the impact that physical or emotional distress can have. Findings suggest that when parents or caregivers of children with growth hormone deficiency report symptoms of stress, anxiety and depression, so does the child they ...
2025-07-12
SAN FRANCISCO—Oxytocin, often called “the love hormone,” may play a protective role in mood disturbances triggered by sleep loss and hormonal shifts during key reproductive transitions like postpartum and menopause, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
Researchers at Brigham and Women’s Hospital and Harvard Medical School studied the combined impact of sleep interruption and estrogen suppression on mood and oxytocin levels in healthy premenopausal women. Their findings suggest that oxytocin may help reduce the negative mood effects brought on by fragmented sleep, which ...
2025-07-12
SAN FRANCISCO—The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
"Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes,” said study author Amanda Kucinskas, ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.003
This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
Acute liver injury (ALI) serves as a critical precursor and major etiological factor in the progression and ultimate manifestation of various hepatic disorders. The prevention and treatment of ALI is still a serious global challenge. Given the limited therapeutic options for ALI, exploring novel targeted therapeutic agents becomes imperative. The potential therapeutic ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.018
This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1.
A major obstacle in type 2 diabetes mellitus (T2DM) is sleep fragmentation (SF), which negatively affects testicular function. However, the underlying mechanisms remain to be elucidated. This study demonstrated that SF induces testicular damage through a mechanism involving lipid metabolism, ...
2025-07-11
https://doi.org/10.1016/j.apsb.2025.05.013
This new article publication from Acta Pharmaceutica Sinica B, discusses how single-cell RNA sequencing reveals that Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic cells.
Colorectal tumorigenesis generally progresses from adenoma to adenocarcinoma, accompanied by dynamic changes in the tumor microenvironment (TME). A randomized controlled trial has confirmed the efficacy and safety of Shen-Bai-Jie-Du decoction (SBJDD) in preventing colorectal ...
2025-07-11
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/15/issue/7
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
APSB is a monthly journal, in English, which publishes ...
2025-07-11
In a first for the field, researchers from The Grainger College of Engineering at the University of Illinois Urbana-Champaign have reported a photopumped lasing from a buried dielectric photonic-crystal surface-emitting laser emitting at room temperature and an eye-safe wavelength. Their findings, published in IEEE Photonics Journal, improve upon current laser design and open new avenues for defense applications.
For decades, the lab of Kent Choquette, professor of electrical and computer engineering, have explored VCSELs, a type of surface-emitting laser used in common technology like smartphones, laser printers, barcode scanners, and even vehicles. But ...
2025-07-11
A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they experienced positive outcomes that support use of targeted radiation in the future for such patients. Results are published in the Journal of Clinical Oncology.
“Despite being the historical standard, whole brain radiation might not be necessary for all patients,” said first author Ayal Aizer, MD, MHS, director of Central Nervous System Radiation Oncology at Brigham and Women’s Hospital, a founding member of the ...
LAST 30 PRESS RELEASES:
[Press-News.org] Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss
Postmenopausal women lost more weight with simultaneous medication use